Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico
Pluri (NASDAQ/TASE: PLUR) subsidiary Coffeesai signed a collaboration with the Instituto del Café de Chiapas on Oct 8, 2025 to advance cell-based coffee manufacturing in Chiapas, Mexico. The agreement establishes a three-phase roadmap: cell line development, pilot-scale 3D bioreactor biofarming in Chiapas, and evaluation of commercial-scale manufacturing subject to definitive agreements and approvals. The partnership aims for non-dilutive license and technology-transfer revenues, royalty-bearing models and joint ventures to access the >$250B global coffee market. Coffeesai will begin Phase 1 immediately to validate cell lines, then deploy pilot-scale operations to test scalability and process robustness.
Pluri (NASDAQ/TASE: PLUR) sussidiaria Coffeesai ha firmato una collaborazione con l'Instituto del Café de Chiapas l'8 ottobre 2025 per avanzare la produzione di caffè cellulare a Chiapas, Messico. L'accordo prevede una tabella di marcia in tre fasi: sviluppo delle linee cellulari, biofabbricazione pilota su bioreattori 3D a Chiapas e valutazione della produzione su scala commerciale soggetta ad accordi definitivi e approvazioni. La partnership punta a ricavi da licenze non diluitive e trasferimento di tecnologia, modelli basati su royalties e joint ventures per accedere al mercato globale del caffè da oltre 250 miliardi di dollari. Coffeesai inizierà immediatamente la Fase 1 per convalidare le linee cellulari, poi implementerà operazioni su scala pilota per testare scalabilità e robustezza del processo.
Pluri (NASDAQ/TASE: PLUR) es una subsidiaria de Coffeesai que firmó una colaboración con el Instituto del Café de Chiapas el 8 de octubre de 2025 para avanzar la fabricación de café a base de células en Chiapas, México. El acuerdo establece una hoja de ruta de tres fases: desarrollo de líneas celulares, bioproducción piloto a escala 3D en Chiapas y evaluación de la fabricación a escala comercial sujeto a acuerdos definitivos y aprobaciones. La asociación apunta a ingresos por licencias no dilutivas y transferencia de tecnología, modelos con regalías y empresas conjuntas para acceder al mercado global del café, valorado en más de 250 mil millones de dólares. Coffeesai iniciará la Fase 1 de inmediato para validar las líneas celulares, y luego desplegará operaciones a escala piloto para probar la escalabilidad y la robustez del proceso.
Pluri (NASDAQ/TASE: PLUR)의 자회사 Coffeesai가 2025년 10월 8일 멕시코 치아파스주에 위치한 Chiapas 커피 연구소와 협력을 맺어 세포 기반 커피 제조를 추진합니다. 이 계약은 3단계 로드맵을 설정합니다: 세포주 개발, 치아파스에서의 3D 바이오리액터 파일럿 스케일 바이오파밍, 그리고 확정 계약 및 승인에 따른 상용 규모 제조 평가. 파트너십은 비희석 면허 및 기술 이전 수익, 로열티 기반 모델 및 합작투자로 2,500억 달러 이상인 글로벌 커피 시장에 접근하는 것을 목표로 합니다. Coffeesai는 먼저 1단계를 즉시 시작해 세포주를 검증하고, 그 다음 파일럿 규모의 운영을 배치해 확장성 및 공정 강건성을 시험합니다.
Pluri (NASDAQ/TASE: PLUR), filiale de Coffeesai, a signé une collaboration avec l'Institut du Café de Chiapas le 8 octobre 2025 pour faire progresser la fabrication de café à base de cellules à Chiapas, Mexique. L'accord établit une feuille de route en trois phases: le développement de lignées cellulaires, la bio-fermentation pilote à l’échelle 3D à Chiapas et l’évaluation de la fabrication à l’échelle commerciale sous réserve d’accords définitifs et d’approbations. Le partenariat vise des revenus de licences non dilutifs et de transfert de technologie, des modèles basés sur les royalties et des coentreprises pour accéder au marché mondial du café, évalué à plus de 2500 milliards de dollars. Coffeesai commencera immédiatement la Phase 1 pour valider les lignées cellulaires, puis déployera des opérations à l’échelle pilote pour tester l’évolutivité et la robustesse du procédé.
Pluri (NASDAQ/TASE: PLUR) Tochtergesellschaft Coffeesai hat eine Zusammenarbeit mit dem Instituto del Café de Chiapas am 8. Oktober 2025 unterzeichnet, um die zellbasierte Kaffeeherstellung in Chiapas, Mexiko, voranzutreiben. Die Vereinbarung sieht eine drei-Phasen-Roadmap vor: Entwicklung von Zelllinien, pilothafte 3D-Bioreaktor-Biofarming in Chiapas und Bewertung der kommerziellen Produktion, vorbehaltlich endgültiger Vereinbarungen und Genehmigungen. Die Partnerschaft zielt auf Einnahmen aus nicht-dilutiven Lizenzen und Technologietransfer, royalties-basierte Modelle und Joint Ventures ab, um den globalen Kaffeemarkt im Wert von über 2500 Milliarden US-Dollar zu erschließen. Coffeesai wird unmittelbar Phase 1 beginnen, um Zelllinien zu validieren, und anschließend Pilotbetriebe einsetzen, um Skalierbarkeit und Prozessrobustheit zu testen.
Pluri (NASDAQ/TASE: PLUR) هي شركة تابعة لـ Coffeesai ووقعت تعاوناً مع معهد قهوة تشياباس في 8 أكتوبر 2025 للمضي قدماً في تصنيع القهوة المعتمدة على الخلايا في تشياباس، المكسيك. ينص الاتفاق على خريطة طريق ثلاث مراحل: تطوير خطوط الخلايا، الزراعة الحيوية على مقياس تجريبي في بيئة حيوية ثلاثية الأبعاد في تشياباس، وتقييم التصنيع على نطاق تجاري رهناً باتفاقات نهائية وموافقات. يسعى الشراكة إلى إيرادات من تراخيص غير مخفضة ونقل تقنية، ونماذج تعتمد على العوائد الملكية ومشروعات مشتركة للوصول إلى سوق القهوة العالمي الذي يتجاوز 250 بليون دولار. ستبدأ Coffeesai بالمرحلة 1 فوراً للتحقق من صحة خطوط الخلايا، ثم ستنفذ عمليات مقياس تجريبي لاختبار القابلية للتوسع ومرونة العملية.
Pluri（纳斯达克/ TASE：PLUR） 的子公司 Coffeesai 已于2025年10月8日与 Chiapas 巧咖啡研究所签署合作协议，在墨西哥恰帕斯推进细胞基咖啡制造。协议设定了一个三阶段路线图：开发细胞系、在恰帕斯进行3D 生物反应器的 Pilot 规模生物养殖，以及在达成最终协议与批准后评估商业规模制造。该伙伴关系的目标是非稀释性许可与技术转让收入、基于特许权使用费的模式以及合资企业，以进入全球超过2500亿美元的咖啡市场。 Coffeesai 将立即开始第一阶段以验证细胞系，然后部署 Pilot 规模运营以测试可扩展性与工艺鲁棒性。
- Three-phase roadmap: cell lines → pilot biofarming → commercial-scale evaluation
- Pilot-scale 3D bioreactor deployment planned in Chiapas
- Access to a >$250B global coffee market opportunity
- Potential non-dilutive license and royalty revenue models
- Commercial-scale manufacturing conditional on definitive agreements and approvals
- Pilot-scale validation required to confirm scalability and process robustness
Insights
State-backed collaboration creates a staged, low-capex route to validate cell-based coffee production in Chiapas; commercial outcomes remain early and conditional.
The agreement sets a clear three-phase path: build a cell line bank, run pilot-scale 3D bioreactor biofarming, and evaluate commercial-scale manufacturing. The structure targets non-dilutive revenue via licensing and royalties and aims to leverage local production know‑how to access a global coffee market exceeding
Key dependencies create execution risk: successful cell line validation, scalable bioreactor performance in local conditions, and customary approvals or definitive commercial agreements. Watch near-term deliverables: Phase 1 cell bank establishment and validation results, pilot-scale process metrics (yield, reproducibility, cost per unit), and any definitive commercial agreements; expect measurable updates within 6–24 months from
- State-backed collaboration outlines a multi-phase, capital-light path from cell line development to pilot-scale biofarming and evaluation of commercial-scale manufacturing in Chiapas
- Coffeesai leverages Pluri’s proprietary 3D cell expansion platform and two decades of expertise to pioneer cell-based coffee solutions resilient to climate change, land constraints, and market volatility
- The global coffee market exceeded
$250B in 2024 and is projected to surpass$350B by 2030 (CAGR5.3% from 2025 to 2030), creating a significant opportunity for scalable, cost-competitive production
HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced that Coffeesai Ltd. (“Coffeesai”), its wholly owned subsidiary developing sustainable cell-based coffee products, has signed an agreement with the Instituto del Café de Chiapas (INCAFECH), a public body of the State of Chiapas, Mexico, to advance cell-based coffee manufacturing in Mexico.
Under the collaboration agreement, the parties aim to progress along a three-phase roadmap designed to de-risk commercialization:
- Cell Line Development: Establish a bank of coffee cell lines using Coffeesai’s technology.
- Pilot-Scale Biofarming: Deploy Coffeesai’s 3D bioreactor in Chiapas to validate scalability and process robustness.
- Commercial-Scale Manufacturing: Explore full-scale facilities for industrial production, subject to entry into definitive agreements and customary approvals.
Why Chiapas, why now: Chiapas is Mexico’s leading coffee-growing region, and Mexico is among the world’s top coffee-producing countries. Pluri believes that establishing operations in Chiapas positions the state as a hub for cell-based coffee innovation, blending cutting-edge biotechnology with a deep local coffee tradition.
Structured to Create Tangible Shareholder Value
- License and Technology Transfer: Potential non-dilutive revenues from Coffeesai’s proprietary cultivation knowhow.
- Recurring Revenue Streams: Royalty-bearing models, joint ventures, and potential sales tied to large-scale production.
- Market Expansion: Embedding Coffeesai’s platform in a top-producing country accelerates commercialization and access to the
$250B + global market. - Supply Chain Resilience and Environmental, Social and Governance (ESG): Consistent, high-quality output independent of climate and arable land constraints, supporting sustainable growth.
Leadership Commentary
“The State of Chiapas has always been a leader in coffee production, and now we aim to lead in coffee innovation,” said Jorge Baldemar Utrilla Robles, Director of the Instituto del Café de Chiapas. “By partnering with Coffeesai and Pluri, we are bringing cutting-edge biotechnology to our region, strengthening our farmers’ future, creating jobs, and positioning Chiapas as a global reference point for the future of coffee.”
“Coffeesai is ready to execute,” said Ami Herman, Chief Executive Officer of Coffeesai. “We will immediately begin Phase 1 by establishing and validating cell lines in Chiapas, followed by pilot-scale deployment of our bioreactors. Each milestone brings us closer to a commercial model that establishes Coffeesai as a leader in sustainable coffee production.”
“We are building the foundation for cost-competitive, commercial-scale cell-based coffee production in Mexico,” said Yaky Yanay, Chairman of Coffeesai and Chief Executive Officer and President of Pluri. “This collaboration is not only about innovation; it is about creating a revenue-generating model aligned with our shareholders’ interests while transforming the future of coffee.”
About Pluri Inc.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, and offers Contract Development and Manufacturing Organization (CDMO) services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
About Coffeesai
Coffeesai is Pluri’s cell-based coffee subsidiary, creating cell-based coffee in labs rather than traditional fields and eliminating the negative environmental impact associated with conventional coffee farming. Coffee consumption has surged by
About Instituto del Café de Chiapas
The Instituto del Café de Chiapas is a decentralized public body of the State of Chiapas, Mexico, dedicated to advancing coffee production, supporting local farmers, and fostering innovation. Chiapas produces more than
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Coffeesai’s technology and its abilities to leverage Pluri’s platform and expertise; the global coffee market size projections; Pluri’s ability to maintain its collaboration with the Instituto del Café de Chiapas and accomplish successfully, or at all, the collaboration three-phase roadmap; Chiapas positioning as a hub for cell-based coffee innovation and its leadership in coffee innovation; the partnership’s potential as a blend of biotechnology and tradition and its ability to drive the advancement of cell-based coffee manufacturing; the expected future shareholders value creation through license and technology transfer, recurring revenue streams, market expansion and ESG; the belief that the partnership will bring cutting-edge biotechnology to the State of Chiapas, strengthen farmers’ future, create jobs, and position Chiapas as a global reference point for the future of coffee; the expectation to immediately begin the first phase of cell line development followed by the second phase of pilot-scale deployment of biocreators; the expectation that Coffeesai will be positioned as a leader in sustainable coffee production; and the collaboration’s ability to create a revenue-generating model and to transform the future of coffee. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the completed collaboration may not be realized as anticipated; changes in technology or market conditions; Pluri may face challenges in launching or scaling new products; government approvals and regulatory developments could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; unforeseen scientific or operational challenges; weather conditions may affect production; and intensified competition in the cultivated food space. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
FAQ
What did PLUR announce on October 8, 2025 regarding Coffeesai (PLUR)?
What are Coffeesai’s three phases for cell-based coffee in Chiapas?
How could the Coffeesai–Chiapas collaboration affect PLUR revenue?
When will Coffeesai start work in Chiapas and what’s first?
Does the agreement guarantee commercial production in Mexico for PLUR (PLUR)?
